Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with ≥...

Descripción completa

Detalles Bibliográficos
Autores principales: Huen, Auris, Haverkos, Bradley M., Zain, Jasmine, Radhakrishnan, Ramchandren, Lechowicz, Mary Jo, Devata, Sumana, Korman, Neil J., Pinter-Brown, Lauren, Oki, Yasuhiro, Barde, Prajak J., Nair, Ajit, Routhu, Kasi Viswanath, Viswanadha, Srikant, Vakkalanka, Swaroop, Iyer, Swaminathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463651/
https://www.ncbi.nlm.nih.gov/pubmed/32824175
http://dx.doi.org/10.3390/cancers12082293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463651/
https://www.ncbi.nlm.nih.gov/pubmed/32824175
http://dx.doi.org/10.3390/cancers12082293

Ejemplares similares